C4 Therapeutics (CCCC) Competitors $3.01 +0.02 (+0.67%) Closing price 04:00 PM EasternExtended Trading$3.03 +0.02 (+0.63%) As of 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CCCC vs. AVBP, COGT, OCS, BCYC, DNA, IMNM, AVDL, CVAC, CDMO, and NUVBShould you be buying C4 Therapeutics stock or one of its competitors? The main competitors of C4 Therapeutics include ArriVent BioPharma (AVBP), Cogent Biosciences (COGT), Oculis (OCS), Bicycle Therapeutics (BCYC), Ginkgo Bioworks (DNA), Immunome (IMNM), Avadel Pharmaceuticals (AVDL), CureVac (CVAC), Avid Bioservices (CDMO), and Nuvation Bio (NUVB). These companies are all part of the "pharmaceutical products" industry. C4 Therapeutics vs. ArriVent BioPharma Cogent Biosciences Oculis Bicycle Therapeutics Ginkgo Bioworks Immunome Avadel Pharmaceuticals CureVac Avid Bioservices Nuvation Bio C4 Therapeutics (NASDAQ:CCCC) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, community ranking, dividends and analyst recommendations. Which has preferable earnings and valuation, CCCC or AVBP? ArriVent BioPharma has lower revenue, but higher earnings than C4 Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioC4 Therapeutics$33.67M6.31-$132.49M-$1.70-1.77ArriVent BioPharmaN/AN/A-$69.33MN/AN/A Is CCCC or AVBP more profitable? ArriVent BioPharma has a net margin of 0.00% compared to C4 Therapeutics' net margin of -313.35%. C4 Therapeutics' return on equity of -42.45% beat ArriVent BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets C4 Therapeutics-313.35% -42.45% -27.55% ArriVent BioPharma N/A -43.89%-29.67% Do analysts prefer CCCC or AVBP? C4 Therapeutics currently has a consensus target price of $11.60, indicating a potential upside of 285.38%. ArriVent BioPharma has a consensus target price of $38.00, indicating a potential upside of 40.38%. Given C4 Therapeutics' higher probable upside, equities analysts clearly believe C4 Therapeutics is more favorable than ArriVent BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score C4 Therapeutics 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50ArriVent BioPharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer CCCC or AVBP? C4 Therapeutics received 10 more outperform votes than ArriVent BioPharma when rated by MarketBeat users. However, 100.00% of users gave ArriVent BioPharma an outperform vote while only 38.57% of users gave C4 Therapeutics an outperform vote. CompanyUnderperformOutperformC4 TherapeuticsOutperform Votes2738.57% Underperform Votes4361.43% ArriVent BioPharmaOutperform Votes17100.00% Underperform VotesNo Votes Do institutionals and insiders believe in CCCC or AVBP? 78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 8.6% of C4 Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor CCCC or AVBP? In the previous week, C4 Therapeutics had 3 more articles in the media than ArriVent BioPharma. MarketBeat recorded 4 mentions for C4 Therapeutics and 1 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.95 beat C4 Therapeutics' score of 0.18 indicating that ArriVent BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment C4 Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ArriVent BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryC4 Therapeutics beats ArriVent BioPharma on 8 of the 14 factors compared between the two stocks. Get C4 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CCCC vs. The Competition Export to ExcelMetricC4 TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$211.06M$3.12B$5.78B$8.98BDividend YieldN/A1.57%4.78%3.85%P/E Ratio-1.7730.1126.4618.82Price / Sales6.31412.67457.0180.82Price / CashN/A183.5344.0437.47Price / Book0.743.567.634.64Net Income-$132.49M-$71.72M$3.18B$245.69M7 Day Performance-5.35%-2.45%-1.82%-2.63%1 Month Performance-21.82%0.36%0.22%-2.37%1 Year Performance-58.48%-11.50%17.49%13.65% C4 Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CCCCC4 Therapeutics2.7266 of 5 stars$3.01+0.7%$11.60+285.4%-60.6%$211.06M$33.67M-1.77150News CoverageAVBPArriVent BioPharma1.1963 of 5 stars$26.60-0.9%$37.40+40.6%+32.8%$896.34MN/A0.0040COGTCogent Biosciences1.4068 of 5 stars$8.03-1.8%$14.33+78.5%-5.8%$886.99MN/A-3.2480Upcoming EarningsPositive NewsOCSOculis2.7324 of 5 stars$21.590.0%$28.80+33.4%+69.8%$874.40M$980,000.00-11.192BCYCBicycle Therapeutics2.8372 of 5 stars$12.55+0.5%$33.25+164.9%-47.1%$866.58M$26.98M-3.81240DNAGinkgo Bioworks0.8579 of 5 stars$14.73+8.7%$4.58-68.9%N/A$846.38M$217.11M-1.131,218Upcoming EarningsNews CoverageGap UpIMNMImmunome2.9734 of 5 stars$10.40-0.3%$28.60+175.0%-56.0%$829.71M$14.02M-1.2840Positive NewsAVDLAvadel Pharmaceuticals3.9614 of 5 stars$8.61-4.2%$19.88+130.8%-34.1%$829.66M$27.96M-10.9070CVACCureVac4.1022 of 5 stars$3.65flat$10.00+174.0%-5.5%$817.16M$58.18M6.641,172News CoverageCDMOAvid Bioservices2.24 of 5 stars$12.50+0.1%$12.25-2.0%+67.9%$799.18M$139.91M-5.23320High Trading VolumeNUVBNuvation Bio2.0621 of 5 stars$2.28-0.7%$8.20+260.4%+27.2%$765.70MN/A-1.0560 Related Companies and Tools Related Companies ArriVent BioPharma Competitors Cogent Biosciences Competitors Oculis Competitors Bicycle Therapeutics Competitors Ginkgo Bioworks Competitors Immunome Competitors Avadel Pharmaceuticals Competitors CureVac Competitors Avid Bioservices Competitors Nuvation Bio Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CCCC) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share C4 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CCCC Stock Alerts